Introduction
Tumor growth is dependent on nutrients and oxygen supplied by blood vessels. As growth continues the tumor mass develops hypoxic zones, that regulate transcription factors sensing hypoxia, such as the HIFs (1) , and these in turn induce higher levels of proangiogenic proteins to accumulate (2) . As such, vascular endothelial growth factors (VEGFs) are known to be over-expressed in tumors and are major inducing agents of neo-angiogenesis (3) . Released in the tumor microenvironment, the VEGFs bind to vascular endothelial growth factors receptors (VEGFRs) on neighboring endothelial cells and promote growth and development of new blood vessels (4) .
Whilst the pioneering work of Judah Folkman (5) has prompted the development of new antiangiogenic cancer therapies (6) (7) (8) (9) (10) , a continuing issue is that most of the treatments in use currently lead to the selection of highly aggressive and resistant stem-like cancer cells (11) . This subpopulation arises from selection pressures brought about by the anoxic microenvironment. Tumors adapt well to harsh hypoxia and low pH through rescue mechanisms, such as using anaerobic metabolism via the glycolysis pathway, as well as inducing multidrug resistance receptors. In these ways the cells enter a dedifferentiation process which confers a stem-like and highly aggressive phenotype (11) (12) (13) . As a means of avoiding these problems, strategies to treat cancer no longer aim to totally inhibit angiogenesis, but rather are designed to promote blood vessel normalization (14) (15) (16) ) and as such have led to a considerable interest in VEGF-based therapies.
Since VEGF-A is also known to be a strong vascular permeabilization factor (VPF) (4, 17) , increased levels in the tumor make the blood vessels leaky and increase edema. Vessels become incapable of ensuring efficient blood flow, thereby maintaining the hypoxic character of the tumor (18) and leading to continuous VEGFs production. This continuous cycle of events inevitably leads to tumor progression (11) (12) (13) . To counteract this outcome, vessel normalization strategies aim to reduce hypoxia-induced angiogenesis, allow maturation of the vessels in order to reduce cell spreading (19) 4 and restore efficient blood flow thus enhancing oxygen supply. These strategies benefit radiotherapy (14) as well as drug delivery during chemotherapy (20) . Consequently, modulation of VEGF expression rather than total inactivation is the preferred route for vessel normalization [21] .
Gene therapy is a promising new approach to achieve blood vessel normalization. For example, a tumor-selective promoter enables site-specific expression of molecules regulated by the HIF/HRE elements (Hypoxia Inducible Factor/Hypoxia Response Elements) (21) . Since a hypoxic environment is the hallmark of solid tumors, HIF/HRE elements are highly useful for targeted gene therapies. The HRE-inducible sequence allows a tight regulation of events, switching-on at low oxygen tension but, more importantly, switching-off under reoxygenation. This reversibility in the expression of a conditioned angiogenesis inhibitor can be advantageously used in vessel normalization strategies bypassing the need for strictly anti-angiogenic treatments.
In this study, we have designed a conditional gene therapy based on a soluble form of the VEGF receptor-2 (sVEGFR2) (8, 22, 23) to trap and neutralize VEGFs that are pathologically overproduced.
The VEGFRs are a family of tyrosine kinase receptors (TKRs) composed of seven extracellular immunoglobulin (Ig)-like domains, a hydrophobic transmembrane region and a cytoplasmic section containing the tyrosine kinase domain (TKD) (24) . Binding of dimerized VEGFs on the VEGFRs allows the TKD transphosphorylation, downstream signaling and activation of survival, proliferation, matrix remodeling and cell migration (25) . VEGFR-2 is directly involved in angiogenesis, since it mediates the growth of endothelial cells and their permeability to cells and molecules upon binding of VEGFs. In contrast to VEGFR2, VEGFR-1 has been described to have a regulatory role in angiogenesis and, VEGFR-3 is thought to act mainly during embryogenesis and lymphangiogenesis (26, 27) .
Amongst the VEGFRs, VEGFR-2 can bind to VEGF-A, C, D, and E, but not to B. Since proteolytic hydrolysis of the membrane form of VEGFR-2 is a natural regulatory mechanism (28) form constitutes a potent VEGF-trap, providing its occurrence is limited to the pathological site. New tools such as specific cell carriers, to ensure selective and conditional expression of VEGFR genes, remain a requirement to fully realize the potential of this strategy in cancer therapy.
Moreover, VEGFRs are often expressed by tumor cells in addition to endothelial cells. Targeting VEGF by VEGFRs gene therapy may thus additionally affect tumor proliferation by depleting a growth factor from its environment (14) (15) (16) . This work demonstrates the beneficial effect of such regulated anti-VEGF approach by its simultaneous action on the endothelium and the tumor cells, improving the efficacy of the treatment through vasculature normalization rather than destruction, as the future of cancer therapy (14) .
Here, we have taken advantage of the hypoxic tumor environment and regulated the expression of soluble VEGFR2 by the inclusion of Hypoxia Response Elements (HRE) (29, 30) driven by a minimal CMV promoter. Moreover, to confirm the selectivity of our construct, a near infrared reporter was integrated into the vector. It encoded the IFP1.4, an intrinsic fluorescent protein enabling real time cell visualization (31) .
For the first time, such a vector permits efficient and tumor specific expression of msVEGFR2, modulated by tumor microenvironmental conditions. The mechanism of interaction of msVEGR2 with its ligand was shown and quantified. Anti-angiogenic as well as anti-tumor growth properties were estimated. Moreover, it was found in vivo, that both effects towards tumor cells and endothelial cells occurred through the control of VEGF-A resulting in the inhibition of cancer cell proliferation and in vessel normalization. 
Materials and methods

Cell culture and oxygen regulation
MLuMEC,FVB and MBrMEC,FVB (32) are mature endothelial cell models from FVB mouse lung and brain cultured as published (32) . HMEC-1 (33), B16F10 cells (ATCC, CRL-6475) and HEK293 cells (ATCC, CRL-10852) were cultured high glucose containing medium (Gibco Invitrogen).
Supplied cell lines were not further authenticated. Details for cell culture are given in supplementary data.
Hypoxia was obtained by introducing a stabilized gas mixture (Witt Gas mixer, Witt France) 94 % 
Animal models
All animal experiments were approved by the CNREEA 03 ethics committee. 
Quantification of msVEGFR2
The secreted msVEGFR2 was analyzed by ELISA duoset R&D kit (DY1558B, R&D systems, USA) (see detailed procedures in Supplementary data).
Surface Plasmon Resonance (SPR) assays
SPR analyses were performed with a Biacore 3000 (Biacore AB, Uppsala, Sweden 
Cell Proliferation Assay
MLuMEC,FVB and B16F10 cell proliferation and effect of conditioned supernatants was measured by BrdU incorporation according to the manufacturer's instructions (Cell Proliferation ELISA, BrdU, Roche) and detailed in Supplementary data.
In Vitro Angiogenesis Assays
In vitro tests for angiogenesis were adapted from (35) as reported in supplementary data. and analyzed using CellQuest software (BD Biosciences) after labeling with anti VEGFR1,2,3
In vivo angiogenesis assay
antibodies. Detailed procedure is described in Supplementary data.
In situ oxygen tension measurement
Tumor tissue pO 2 measurement was performed with a fiber-optic oxygen-sensing device of the fluorescent light emitted by the ruthenium, the partial oxygen pressure in the probe tip was immediately determined to give a pO 2 measure in several sites of the tumor (depending of the tumor size). Each OxyLite probe was calibrated by the manufacturer prior to its delivery, and used according to the manufacturer's instruction.
Immunohistochemistry
Tumor cryosections were fluorescently labelled by specific lectins and monoclonal antibodies and observed by fluorescence microscopy (Zeiss observer).Methods are det ailed in Supplementary data.
Plasma collection
Plasma samples from B16F10 melanoma bearing mice were obtained after anesthesia with isoflurane, followed by heart puncture as detailed in Supplementary section. 
Statistical analysis
All values were expressed as means ± SD. Statistical analysis was conducted by Student t test. Group differences resulting in p = 0.05 by student t test were considered statistically significant.
Results
Construction of pIFP-HRE-msVEGFR2 Vector and pHRE-msVEGFR2
The structure of the plasmid is reported in Supplementary Figure The first expression cassette was controlled by ELISA for measurement of msVEGFR2 secretion in the medium by transfected cells when placed under hypoxia (<1 % oxygen) compared to normoxia (18.75% oxygen). Transient transfection was performed on HEK293 cells and the supernatant was conditioned for 48h. Figure 1A (left) shows that msVEGFR2 production was indeed induced upon hypoxia, confirming that hypoxia-regulation of msVEGFR2 expression is efficient. Some leakage was observed since a basal level of msVEGFR2 (13 ng/mL/10 5 cells) was produced by transfected cells in normoxia. As a consequence, a shorter minCMV promoter was constructed by restriction endonuclease digestion leading to 3' promoter DNA excision (Supplementary Figure S2 and Figure   1A , left). The shortened promoter substantially reduced leakiness in terms of msVEGFR2 production in normoxia (5ng/mL/10 5 cells, up to 60% reduction) ( Figure 1A , left). Thus, the "short minCMV"
promoter was used to design the following two vectors: pIFP-HRE-msVEGFR2 and pHREmsVEGFR2, used in the subsequent experiments. The final construct pIFP-HREmsVEGFR2 was transfected into human HEK293, as well as into murine B16F10 melanoma cells, to assess its efficacy and its hypoxia-dependent regulation in human and murine species. As previously demonstrated (36, 37), and in our hands as well, the CMV promoter was stronger in human than murine cells ( Figure 1A , right). This reduced efficacy of the CMV promoter highlighted the differences in the levels of msVEGFR2 expression observed in hypoxia vs normoxia, in murine cells where hypoxia induced a 6.0 fold increase as compared to a 1.7 fold increase in human cells. The oxygen threshold value necessary to turn-on msVEGFR2 expression was analyzed at various oxygen partial pressures: 21 %, 5 %, 3 % and 1 %. msVEGFR2 levels were estimated by ELISA in supernatants from HEK-IFP-msVEGFR2 cells after a 48h incubation in hypoxia. As shown in Figure   1C (top), the hypoxia regulated promoter was switched-on only when oxygen tension decreased to 3 %. This threshold ensured that expression of msVEGFR2 would be restricted to cells within hypoxic microenvironments, such as those encountered in solid tumors. The validation of the switch-off control of msVEGFR2 expression by pO2 was performed upon cells reoxygenation after hypoxia and measurement of the msVEGFR2 production. As shown on Figure 1C (bottom) the production of msVEGFR2 by HEK-IFPmsVEGFR2 cells was totally reversed after a 96h reoxygenation phase.
Engineered cell lines for msVEGFR2 production
Soluble mVEGFR2 binds to its ligand
We anticipated that the soluble VEGF receptor-2 (msVEGFR2) encoded by the pHRE-msVEGFR2 vector would recognize and bind to VEGF. This activity was assessed and quantified by a surface plasmon resonance assay with murine and human VEGF-A using hypoxia-conditioned supernatant 
Proliferation of Endothelial and Melanoma Cells is inhibited by msVEGFR2
msVEGFR2-conditioned supernatant was able to inhibit VEGF-induced proliferation of tumor cells and angiogenesis in terms of endothelial cell growth. This was assessed on the B16F10 murine melanoma cells and on mature murine endothelial cells MLuMEC,FVB (32) . Each of these VEGF- 
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responsive cell line was incubated with a 48h hypoxia-conditioned supernatant containing msVEGFR2 (60 ng/mL) from HEK-IFP-msVEGFR2 and compared to an HEK-IFP control. Figure 2B shows that both tumor and endothelial lines displayed a strongly reduced proliferation by 60 %. This indicates that expressed msVEGFR2 was active to recognize, bind and neutralize the mVEGFs ( Figure 2B ). As the above data assume the presence of VEGF receptors on the tested cells, this was assessed in flow cytometry experiments reported in Figure 2C . VEGFR1, R2 and R3 presence and modulation by hypoxia were investigated at the single cell surface level. Figure 2C (top a, b) shows that B16F10 cells express the VEGF receptors 1 and 2 in normoxia. This expression is clearly increased on the cell surface upon hypoxia ( Figure 2C top, d , e) while VEGFR3 was absent in both conditions ( Figure 2C top, c, f) (38). Figure 2C 
msVEGFR2 decreases VEGF-induced angiogenesis in vitro
Anti-angiogenic potential of the msVEGFR2 protein was assessed in a Matrigel TM angiogenesis assay.
The msVEGFR2 activity was evaluated in a first attempt after incubation of the conditioned supernatants with HMEC-1 human endothelial cells. As shown in Figure 3A , the organized pseudovessel network was drastically reduced when endothelial cells had been exposed to msVEGFR2 (70 ng/mL) containing supernatant compared to control HEK-IFP cell supernatant ( Figure 3A , right).
neo-angiogenesis is inhibited in vivo by msVEGFR2 expression
To determine whether the msVEGFR2 can modulate angiogenesis in vivo, a Matrigel TM plug model was used. Matrigel™ plugs containing either HEK-IFP-msVEGFR2 ( Figure 3B , right) or HEK-IFP ( Figure 3B , left) cells were injected as described in Materials and Methods. Mice bearing control
Matrigel plugs containing HEK-IFP cells displayed an extensive vascularization ( Figure 3B, left) while plugs containing msVEGFR2 producing cells appeared to be non angiogenic ( Figure 3B , right).
Plug limits could be clearly delineated by mCherry fluorescence ( Figure 3B ). 
vascularization in plugs containing msVEGFR2 producing cells was confirmed by fluorescent imaging of blood vessels reported by FTC-labelled dextran, intravenously injected to trace the vasculature ( Figure 3C) . FTC-dextran angiography shows that Matrigel did induce neo-angiogenesis ( Figure 3B and C, a, b) as compared to control skin ( Figure 3C, c) . Confirming the above data, plugs containing msVEGFR2-secreting cells displayed reduced neo-angiogenesis in terms of vessel numbers ( Figure   3C , b) compared to controls ( Figure 3C, a, white arrows) . Angiogenesis appeared less chaotic and vessels looked better formed in the presence of msVEGFR2 secreting cells ( Figure 3C , b, white arrow). These results prove that msVEGFR2 is active in vivo to decrease neo-angiogenesis by VEGF trapping and apparent pruning ( Figure 3C, b) suggests blood vessels normalization. These data suggest an effect on tumor angiogenesis. Thus vessels structure was observed and function assessed. Consequently, pericyte recruitment and vessel structure were studied by histochemical staining of tumors frozen and fixed sections. Figure 5C shows that pO 2 , measured by Ru fluorescence quenching was increased in msVEGFR2 expressing melanoma tumors.
As kinetics of tumor growth (supplementary Figure S5E ) indicated heterogeneity among tumor groups, pO 2 was assessed in tumors of similar volume. Independently of size, tumors from B16F10wt were more hypoxic than tumors from the msVEGFR2 producing clones 13.3 and 16.4. Since the effect on tumor oxygenation is not due to the tumor size, it means that decrease in VEGF production may result from the normalization of the vasculature upon pO 2 increase as previously shown (39).
Fluorescent imaging properties of the pIFP-msVEGFR2 transfected cells
Stably transfected HEK293 and B16F10 cells by the expressing sequence reported on Figure 6A , were used to evaluate in vitro IFP1.4 (excitation and emission maxima at 684 and 708 nm respectively) protein expression and its reporter protein mCherry (excitation and emission maxima at 587 nm and 610 nm) by fluorescence microscopy ( Figure 6B , a-d, and Figure 6C Similarly, the expression of mCherry, cloned after IRES downstream the IFP1.4 coding sequence was detected ( Figure 6B , a, c and Figure C, a, c) . This allows cell tracking in non near infrared optical settings and reporting of the IFP1. 4 . Figure 6B (a-d) and Figure 6C 
Discussion
Given the role of angiogenesis in tumor growth and progression, the strategy that aims at targeting tumor vasculature is of high interest. VEGFs are the most efficient activators of angiogenesis and VEGF-A, being the key inducer, is the good candidate to control.
In this study, we have developed a regulated therapeutic gene for cancer treatment by hypoxia-driven VEGF trapping by the soluble form of its receptor: msVEGFR2. Interaction of the produced msVEGFR2 with the murine VEGF-A was quantified by surface plasmon resonance. The kinetics constants qualified it as a VEGF-trap comparable to the previously described DAAP (10 
biological efficacy was proven by its efficient effect on decreasing angiogenesis in vitro and in vivo, and diminishing tumor cell proliferation. This therapy consequently acts on both tumor and endothelial targets.
The described vector, is mainly adapted for its 3x HRE combination pattern that appears an optimized enhancer cassette to modulate the truncated CMV activity (minCMV promoter) (29) . Such combination allows gene expression to be restricted to hypoxic environment. In the present study, we have fused this conditional sequence to msVEGFR2 coding sequence. According to published results from Holash et al. (8) , such soluble form of the VEGFR2 was efficient to trap the VEGF and acts as a natural cell regulator (40).
Physioxia (41-43), the partial oxygen tension characteristic of a tissue/organ in physiological context has deep implications for hypoxia-mediated therapies. Indeed, the hypoxia-driven expression was dependent of strong O 2 deprivation. A threshold was determined indicating that the therapeutic gene would be expressed only in hypoxic environment and restricted to it, thus avoiding or limiting side effects as confirmed by the reversibility of the gene expression upon reoxygenation. This confirms that such therapy is a mean to control rather than destroy the angiogenic process leading to a normalization of the vessels (39).
Validating its further use in vivo, the produced msVEGFR2 protein was indeed angiostatic, as demonstrated here by the Matrigel TM plug assay. As such matrix contains pro-angiogenic factors, msVEGFR2 activity on angiogenesis is minimized, and thus msVEGFR2 works out the proangiogenic effect of the Matrigel TM .
This was validated in vivo, using a tumor model for msVEGFR2 expression showing tumor reduction and angiogenesis normalization, with pericytes recruitment and restoration of vessels function illustrated by intratumor pO2 increase (42, 44).
This regulated and targeted therapy brings an important breakthrough into anti-angiogenesis strategies by overtaking their limitations. Indeed, anti-angiogenic therapies able to act via vessel normalization are more promising than vessels destruction which is achieved here by the hypoxia-regulated and reversible sequence. This strategy will help fighting cancer resistance, stem-like cancer cell selection 
and enhance the efficacy of combinatory chemo-and radio-therapy by hypoxia compensation (39, 43, 45). Moreover, the designed vector is applicable to in vivo imaging, since it expresses the Infrared Fluorescent Protein (IFP1.4) and mCherry.
In that respect, our strategy opens opportunities to combine gene-with cell-targeting therapies or viruses-therapies (i.e. oncolytic viruses or gene transfer). Its flexibility presents an invaluable advantage in view of future in vivo applications (46, 47) .
It is noteworthy that all VEGF-inhibitors (antibodies, decoys, traps and small molecule inhibitors) induce harsh acidic and oxygen-deprived conditions which lead to the selection of resistant tumor cells that explain therapy failures and enhancement of tumor invasiveness and metastasis (11, 13, 48) .
Thus a VEGF-trap, combined to hypoxia regulation, will provide an efficient strategy to optimize the control of tumor angiogenesis, inhibit metastasis, vascular leakage, and limit the tumor growth.
Moreover, extended endogenous VEGF-A blockade treatments are correlated with toxicity such as hypertension (49) . This might be limited by the described strategy thanks to the localized and 
